Virus-like particles presenting interleukin-33 molecules

Avian lymphoid leukosis: Virus-like particles in kidney Cells

Virus-like particles as vaccine.

This review presents data on commercial and experimental virus-like particle (VLP) vaccines, including description of VLP vaccines against influenza. Virus-like particles are multimeric, sometimes multiprotein nanostructures assembled from viral structural proteins and are devoid of any genetic material. VLPs present repetitive high-density displays of viral surface proteins. Importantly, they ...

Mannosylation of Virus-Like Particles Enhances Internalization by Antigen Presenting Cells

Internalization of peptides by antigen presenting cells is crucial for the initiation of the adaptive immune response. Mannosylation has been demonstrated to enhance antigen uptake through mannose receptors, leading to improved immune responses. In this study we test the effect of surface mannosylation of protein-based virus-like particles (VLP) derived from Rabbit hemorrhagic disease virus (RH...

Chimeric virus-like particles presenting common neutralizing epitopes of enterovirus 71

To develop an effective vaccine against multiple genotypes of enterovirus 71 (EV71), we generated chimeric virus-like particles (VLPs) repetitively displaying the common neutralizing epitopes of EV71 and evaluated their immunogenicities in mice. The two conserved epitopes, encompassing amino acids 163-177 and 208-222 of VP1 of EV71, were fused to hepatitis B core antigen (HBcAg) and expressed i...

Virus-like particles as drug delivery vectors.

Virus-like particles (VLPs) assemble spontaneously during the viral cycle or in heterologous systems during expression of viral structural protein. Depending on the complexity of the VLPs, they can be obtained by expression in prokaryotic or eukaryotic expression system from the suitable recombinant vectors, or formed in cell-free conditions. Moreover, they can be built from proteins of a singl...